Every material Form 8-K INTELLIGENT BIO SOLUTIONS INC. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Intelligent Bio Solutions adopted Second Amended and Restated Bylaws on October 12, 2026. The main change clarifies that non-director matters are decided by a majority of votes cast, excluding broker non-votes and abstentions, which now have no effect on the outcome. The company also furnished an investor presentation made available on October 13, 2026.
Bylaws adopted by the Board on October 12, 2026, effective on that date
Non-director matters decided by majority of votes cast, excluding broker non-votes; abstentions also excluded and have no impact
Company furnished investor presentation made available October 13, 2026, posted in the Investors section of www.ibs.inc
Intelligent Bio Solutions disclosed an updated count of its common stock outstanding, reaching 3,316,803 shares as of the close of business on September 10, 2026. The increase reflects the exercise of prefunded warrants for 285,000 shares and the issuance of 4,333 restricted shares under a previously disclosed investor relations advisory agreement. The update is administrative and does not report financial results or guidance.
Total common shares outstanding as of September 10, 2026: 3,316,803
Prefunded warrants exercised for 285,000 shares of common stock
4,333 shares of restricted common stock issued under the February 29, 2024 Investor Relations and Corporate Development Advisory Agreement
Intelligent Bio Solutions said it submitted a 510(k) premarket notification to the FDA seeking clearance of its Intelligent Fingerprinting Drug Screening System for detecting codeine. The company says the submission is based on a 2026 clinical program and that FDA clearance is expected to expand its addressable U.S. market beyond forensic-use-only settings. The filing does not state a clearance timeline or any financial figures.
Submission announced September 9, 2026 for codeine detection on the Intelligent Fingerprinting Drug Screening System
Method Comparison Study reported accuracy above 98%, sensitivity above 94% and 100% specificity across three U.S. clinical sites
Cybersecurity review reported 100% of medium-risk vulnerabilities remediated and all 19 SBOM vulnerabilities resolved
Filing gives no FDA review timeline and no financial results or guidance
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every INTELLIGENT BIO SOLUTIONS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →